Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation
暂无分享,去创建一个
[1] P. Bonnier,et al. Expression of her-2/neu oncogene in breast-cancer - correlation of quantitative immunocytochemistry and prognostic factors. , 1992, International journal of oncology.
[2] T. Singleton,et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. , 1992, Human pathology.
[3] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] B. Ljung,et al. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. , 1992, Oncogene.
[5] H. Preisler,et al. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. , 1992, Cancer research.
[6] J. Foekens,et al. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. , 1992, European journal of cancer.
[7] A. Harris,et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.
[8] T. Perren. c-erbB-2 oncogene as a prognostic marker in breast cancer. , 1991, British Journal of Cancer.
[9] D. Birnbaum,et al. Characterization of a murine glyceraldehyde-3-phosphate dehydrogenase pseudogene. , 1990, Biochimie.
[10] S. Naber,et al. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. , 1990, American journal of clinical pathology.
[11] W. Gullick,et al. NCL‐CB11, a new monoclonal antibody recognizing the internal domain of the c‐erbB‐2 oncogene protein effective for use on formalin‐fixed, paraffin‐embedded tissue , 1990, The Journal of pathology.
[12] S. Skates,et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. , 1989, Cancer research.
[13] S. Steinberg,et al. Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. , 1989, Cancer research.
[14] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[15] D. Birnbaum,et al. Characterization of the HST-related FGF.6 gene, a new member of the fibroblast growth factor gene family. , 1989, Oncogene.
[16] R. Zeillinger,et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. , 1989, Oncogene.
[17] T. Powles,et al. Immunohistochemical distribution of c‐erbB‐2 in infiltrating and in situ breast cancer , 1988, International journal of cancer.
[18] M. J. van de Vijver,et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.
[19] B. Gusterson,et al. c-erbB-2 expression in benign and malignant breast disease. , 1988, British Journal of Cancer.
[20] J E Talmadge,et al. Evidence for a novel gene associated with low tumor metastatic potential. , 1988, Journal of the National Cancer Institute.
[21] N. Azumi,et al. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on formalin- and alcohol-fixed tumors. , 1987, American journal of clinical pathology.
[22] W. Gullick,et al. OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.
[23] M. Kraus,et al. Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms. , 1987, The EMBO journal.
[24] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[25] J. Jacquemier,et al. [Immunohistochemical study using monoclonal antibodies (H222 SP gamma) of estrogen receptors: correlation with biochemical analysis (by radioligand) of 115 breast carcinomas]. , 1986, Bulletin du cancer.
[26] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.